Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a 12-week, randomized, double-blinded, placebo-controlled trial of telmisartan 80
mg/day as an adjunctive to clozapine or olanzapine therapy, in 70 schizophrenia subjects to
examine telmisartan's effect on glucose metabolism, weight, food intake, resting energy
expenditure, and body composition. In addition, the study will examine insulin's effects on
psychopathology and cognition.
Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, or
Massachusetts General Hospital. Approximately 70 subjects will be enrolled.